Skip to main content

Intelligent Bio Solutions Screening Technologies Poised to Disrupt The Healthcare Sector: INBS, LH, ABT, DGX

Intelligent Bio Solutions Screening Technologies Poised to Disrupt The Healthcare Sector: INBS, LH, ABT, DGX

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology firm at the forefront of developing and marketing rapid, intelligent, cutting-edge, and non-intrusive drug testing and health screening solutions. The company is actively involved in commercializing its smart fingerprinting device for drug testing, which has gained rapid traction in the healthcare market segment. 

Drug testing traditionally involves analysing urine or saliva samples, a process that is often expensive, time-consuming, and poses biohazard risks. The demand for swift, reliable, user-friendly, and cost-effective drug testing methods, particularly in workplaces, is on the rise. Market projections indicate a substantial growth from $5.3 billion in 2023 to an estimated $28.3 billion by 2032, with urine and saliva tests leading the market. Intelligent Bio Solutions is poised to capture a significant market share with its fingerprint testing solution. 

In the competitive landscape, companies like Labcorp (NYSE: LH), Quest Diagnostics (NYSE: DGX), Thermo Fisher Scientific (NYSE: TMO), Abbott Laboratories (NYSE: ABT), and OraSure (Nasdaq: OSUR) offer various drug testing services, including urine and saliva tests with different turnaround times and methodologies. 

Intelligent Bio Solutions' Fingerprinting technology has redirected the company's focus towards a market-ready product. Their drug screening system utilizes advanced technology for detecting drugs in fingerprint sweat, delivering rapid results within minutes. This system is tailored for organizations with regular drug screening needs, promising a paradigm shift in the healthcare sector. 

Moreover, Intelligent Bio Solutions Inc. (NASDAQ: INBS) is experiencing substantial global growth and is on the path to profitability. Analysts argue that the company's shares are currently undervalued, with Ladenburg Thalmann recently issuing a buy rating for Intelligent Bio Solutions Inc. stock, setting a target price of $12 per share. For more insights, read the full TalkMarkets article.


Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.